Cue Biopharma (CUE) Current Assets (2017 - 2026)

Cue Biopharma has disclosed Current Assets across 10 years of filings, most recently posting $26.6 million for Q2 2026.

• In Q2 2026, Current Assets fell 13.68% year-over-year to $26.6 million; the TTM figure through Jun 2026 stood at $26.6 million (down 13.68% YoY), while the FY2025 annual figure was $37.0 million, up 47.12% from the prior year.
• Current Assets came in at $26.6 million for Q2 2026 at Cue Biopharma, down from $37.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $77.2 million in Q4 2022 to a low of $15.9 million in Q1 2025.
• Average Current Assets over 5 years is $47.0 million, with a median of $44.7 million recorded in 2024.
• The largest YoY upside for Current Assets was 47.12% in 2025 against a maximum downside of 64.34% in 2025.
• Over 5 years, Current Assets stood at $77.2 million in 2022, then sank by 33.34% to $51.5 million in 2023, then plunged by 51.14% to $25.1 million in 2024, then soared by 47.12% to $37.0 million in 2025, then slipped by 28.01% to $26.6 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $26.6 million in Q2 2026, $37.0 million in Q4 2025, and $25.8 million in Q3 2025.